Guaifenesin and Potassium Guaiacolsulfonate

Pronunciation

(gwye FEN e sin & poe TASS ee um gwye a kole SUL foe nate)


U.S. Brand Names

Allfen ; Humibid® LA

(reformulation)(reformulation)

Synonyms

Potassium Guaiacolsulfonate and Guaifenesin



Generic Available

No



Use

Temporary control of cough associated with respiratory tract infections and related conditions which are complicated by tenacious mucus and/or mucus plugs and congestion



Pregnancy Risk Factor

C



Pregnancy Implications

Reproduction studies have not been conducted.



Lactation

Excretion in breast milk unknown/not recommended



Contraindications

Hypersensitivity to guaifenesin, potassium guaiacolsulfonate, or any component of the formulation



Warnings/Precautions

Underlying cause of cough should be determined prior to prescribing. Safety and efficacy have not been established in children <6 years of age.



Adverse Reactions

Frequency not defined.

Central nervous system: Dizziness, headache

Dermatologic: Rash, urticaria

Endocrine & metabolic: Uric acid levels decreased

Gastrointestinal: Gastrointestinal discomfort, nausea, vomiting

Postmarketing and/or case reports: Kidney stone formation (with consumption of large quantities of guaifenesin)

Stability

Store at room temperature of 20°C to 25°C (68°F to 77°F), in a dry location.



Mechanism of Action

Guaifenesin and potassium guaiacolsulfonate are both expectorants. Guaifenesin is thought to act as an expectorant by irritating the gastric mucosa and stimulating respiratory tract secretions, thereby increasing respiratory fluid volumes and decreasing mucus viscosity.



Pharmacodynamics/Kinetics

Absorption: Guaifenesin: Well absorbed

Half-life elimination: Guaifenesin: ~1 hour

Excretion: Guaifenesin: Urine (as unchanged drug and metabolites)

Dosage

Oral: Relief of cough:

Children 6-12 years (Allfen): One-half tablet every 12 hours; maximum 1 tablet/24 hours

Children

12 years and Adults (Allfen, Humibid® LA): One tablet every 12 hours; maximum 2 tablets/24 hours

Administration

Extended release tablets should not be crushed or chewed.



Test Interactions

Possible interference with determination of 5-HIAA and VMA; discontinue for 48 hours prior to test.



Dental Health: Effects on Dental Treatment

No significant effects or complications reported



Dental Health: Vasoconstrictor/Local Anesthetic Precautions

No information available to require special precautions



Mental Health: Effects on Mental Status

May cause dizziness or drowsiness



Mental Health: Effects on Psychiatric Treatment

None reported



Dosage Forms

Tablet, sustained release:

Allfen: Guaifenesin 1000 mg and potassium guaiacolsulfonate 150 mg

Humibid® LA: Guaifenesin 600 mg and potassium guaiacolsulfonate 300 mg

Review Date: 1969-12-31 Reviewed By: Keywords: ,
Adam Data Copyright The information provided herein should not be used during any medical emergency or for the diagnosis or treatment of any medical condition. A licensed medical professional should be consulted for diagnosis and treatment of any and all medical conditions. Call 911 for all medical emergencies. Links to other sites are provided for information only--they do not constitute endorsements of those other sites. © 1997- 2010 A.D.A.M., Inc. Any duplication or distribution of the information contained herein is strictly prohibited.

For information 410.787.4000

© 2013 UM Baltimore Washington Medical Center.  All rights reserved.

301 Hospital Drive, Glen Burnie, MD 21061 | 410-787-4000 | TTY 410-787-4498